Nurix Therapeutics, Inc. NRIX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Nurix Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s EBITDA margin?
- Nurix Therapeutics, Inc. (NRIX) reported EBITDA margin of -427.3% in Q4 2025.
- How has Nurix Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Nurix Therapeutics, Inc.'s EBITDA margin decreased by 9.1% year-over-year, from -391.8% to -427.3%.
- What is the long-term trend for Nurix Therapeutics, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s EBITDA margin has grown at a -1.3% compound annual growth rate (CAGR), from -352.1% to -329.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.